Scoping review of ibogaine for addiction: promise, patchy evidence and heart safety concerns

The question

What does the existing research say about ibogaine as a treatment for substance use disorder, and how serious are the concerns about its effects on the heart?

What they did

The authors carried out a scoping review, a type of review that maps out what research exists on a topic rather than combining results statistically. They gathered both laboratory/animal studies and human studies of ibogaine, a compound from the root of the Tabernanthe iboga plant, used for substance use disorder. They focused on reported effects on withdrawal symptoms and craving, on dose-response patterns, and on reported heart-related adverse events.

What they found

The review notes that substance use disorder is linked to roughly 600,000 deaths worldwide each year, largely driven by opioid use, and that approved treatments remain limited in effectiveness. Ibogaine is described as acting on several brain systems at once, which the authors suggest may explain reports of reduced withdrawal symptoms and craving. However, they conclude that the human evidence is fragmented and inconsistent, that available preparations are often not chemically standardized, that regulatory frameworks are missing in many countries, and that concerns about cardiac adverse events remain unresolved. The idea of a neurobiological “reset” is presented as a hypothesis that still needs testing.

The fine print

A scoping review maps the literature but does not pool data or formally assess how reliable each study is, so no overall effect size can be drawn from it. The abstract does not report how many studies or people were included, nor any specific outcome numbers or rates of heart problems. Much of the underlying evidence is preclinical (animal or laboratory) rather than from controlled human trials. This summary is based on the abstract alone.

What it means

Ibogaine continues to attract research interest for addiction because it acts on several brain pathways at once, but this review concludes the human evidence is still too scattered, and the heart safety questions too unsettled, to support routine clinical use.

Evidence grade: Low. A scoping review that narratively summarizes a mix of animal and human studies without pooling results or rating study quality.

This summary is based on the study’s published abstract.